MRD-negative complete remission rate

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%